Stock Track | Cellebrite Soars 5.08% on Strong Q2 Results, New CEO Appointment, and Positive Outlook

Stock Track
08/14

Cellebrite (CLBT) shares surged 5.08% in pre-market trading on Thursday following the release of its impressive second-quarter 2025 financial results, the announcement of a new CEO, and an optimistic future outlook. The digital intelligence solutions provider demonstrated robust growth across key financial metrics, surpassing analyst expectations in several areas.

For Q2 2025, Cellebrite reported revenue of $113.276 million, an 18% year-over-year increase that beat the IBES estimate of $112.2 million. The company's subscription revenue saw a significant 21% rise to $103.0 million, while Annual Recurring Revenue (ARR) grew by 21% to $418.9 million. Adjusted EBITDA came in at $27.885 million, also surpassing the IBES estimate of $27 million, with an impressive margin of 24.6%.

Adding to the positive news, Cellebrite announced the appointment of Thomas E. Hogan as its new CEO. Hogan, who had been serving as interim CEO since January, expressed confidence in the company's growth trajectory and its ability to support customers in law enforcement, defense, and intelligence sectors. The combination of strong financial performance and new leadership appears to have bolstered investor confidence.

Looking ahead, Cellebrite provided an encouraging outlook for Q3 and full-year 2025. The company expects Q3 revenue between $121 million and $126 million, with adjusted EBITDA ranging from $31 million to $34 million. For the full year, Cellebrite projects revenue between $465 million and $475 million, with adjusted EBITDA expected to be between $118 million and $123 million. These projections, along with the company's ongoing expansion in the digital investigation market, seem to have further fueled investor optimism, contributing to the significant pre-market stock price increase.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10